Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

HIV and AIDS are not the same thing. HIV is a virus that attacks the body’s immune system, specifically white blood cells called CD4 T cells, which help the body fight infections. They are also ...

In this cross-sectional study, researchers explored immune activation as a possible mechanism for this seemingly paradoxical response to HIV infection. CD4-cell counts and T-cell activation levels ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

Kidney transplant between donors and recipients with HIV is successful, research shows, which may help addresses the organ ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Telehealth could be a feasible long-term option for people living with HIV, potentially saving them time, effort, and expense ...